Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.04
CBM's Cash to Debt is ranked lower than
79% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CBM: 1.04 )
Ranked among companies with meaningful Cash to Debt only.
CBM' s 10-Year Cash to Debt Range
Min: 0.01  Med: 0.24 Max: No Debt
Current: 1.04
Equity to Asset 0.53
CBM's Equity to Asset is ranked lower than
66% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBM: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
CBM' s 10-Year Equity to Asset Range
Min: 0.22  Med: 0.44 Max: 0.74
Current: 0.53
0.22
0.74
F-Score: 8
Z-Score: 5.92
M-Score: -3.08
WACC vs ROIC
16.42%
25.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.36
CBM's Operating margin (%) is ranked higher than
86% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CBM: 19.36 )
Ranked among companies with meaningful Operating margin (%) only.
CBM' s 10-Year Operating margin (%) Range
Min: -2.77  Med: 12.67 Max: 18.02
Current: 19.36
-2.77
18.02
Net-margin (%) 16.29
CBM's Net-margin (%) is ranked higher than
85% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CBM: 16.29 )
Ranked among companies with meaningful Net-margin (%) only.
CBM' s 10-Year Net-margin (%) Range
Min: -98.33  Med: 6.31 Max: 82.87
Current: 16.29
-98.33
82.87
ROE (%) 26.02
CBM's ROE (%) is ranked higher than
94% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CBM: 26.02 )
Ranked among companies with meaningful ROE (%) only.
CBM' s 10-Year ROE (%) Range
Min: -94.37  Med: 10.55 Max: 120.02
Current: 26.02
-94.37
120.02
ROA (%) 13.39
CBM's ROA (%) is ranked higher than
91% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CBM: 13.39 )
Ranked among companies with meaningful ROA (%) only.
CBM' s 10-Year ROA (%) Range
Min: -37.93  Med: 3.72 Max: 42.71
Current: 13.39
-37.93
42.71
ROC (Joel Greenblatt) (%) 31.19
CBM's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CBM: 31.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CBM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1.19  Med: 13.11 Max: 33.06
Current: 31.19
-1.19
33.06
Revenue Growth (3Y)(%) 11.00
CBM's Revenue Growth (3Y)(%) is ranked higher than
67% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CBM: 11.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CBM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -18  Med: 0.30 Max: 11
Current: 11
-18
11
EBITDA Growth (3Y)(%) 14.90
CBM's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CBM: 14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CBM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27  Med: -0.40 Max: 32.8
Current: 14.9
-27
32.8
EPS Growth (3Y)(%) 58.70
CBM's EPS Growth (3Y)(%) is ranked higher than
95% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CBM: 58.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CBM' s 10-Year EPS Growth (3Y)(%) Range
Min: -21.5  Med: 16.70 Max: 79.7
Current: 58.7
-21.5
79.7
» CBM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CBM Guru Trades in Q3 2014

Chuck Royce 921,629 sh (+15.01%)
Jim Simons 261,500 sh (-20.32%)
» More
Q4 2014

CBM Guru Trades in Q4 2014

Joel Greenblatt 78,575 sh (New)
Paul Tudor Jones 17,728 sh (New)
Chuck Royce 956,112 sh (+3.74%)
Chuck Royce 956,112 sh (unchged)
Jim Simons 154,600 sh (-40.88%)
» More
Q1 2015

CBM Guru Trades in Q1 2015

Jim Simons 407,900 sh (+163.84%)
Paul Tudor Jones 43,435 sh (+145.01%)
Joel Greenblatt 60,855 sh (-22.55%)
Chuck Royce 569,112 sh (-40.48%)
» More
Q2 2015

CBM Guru Trades in Q2 2015

Joel Greenblatt 268,701 sh (+341.54%)
Jim Simons 355,100 sh (-12.94%)
Chuck Royce 424,500 sh (-25.41%)
Paul Tudor Jones 22,492 sh (-48.22%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.88
CBM's P/E(ttm) is ranked higher than
67% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. CBM: 22.88 )
Ranked among companies with meaningful P/E(ttm) only.
CBM' s 10-Year P/E(ttm) Range
Min: 1.05  Med: 15.32 Max: 63.2
Current: 22.88
1.05
63.2
Forward P/E 20.04
CBM's Forward P/E is ranked higher than
59% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. CBM: 20.04 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.70
CBM's PE(NRI) is ranked higher than
66% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. CBM: 23.70 )
Ranked among companies with meaningful PE(NRI) only.
CBM' s 10-Year PE(NRI) Range
Min: 5.17  Med: 15.52 Max: 94.8
Current: 23.7
5.17
94.8
P/B 5.30
CBM's P/B is ranked lower than
60% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CBM: 5.30 )
Ranked among companies with meaningful P/B only.
CBM' s 10-Year P/B Range
Min: 0.61  Med: 1.94 Max: 5.78
Current: 5.3
0.61
5.78
P/S 3.73
CBM's P/S is ranked higher than
77% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. CBM: 3.73 )
Ranked among companies with meaningful P/S only.
CBM' s 10-Year P/S Range
Min: 0.18  Med: 1.26 Max: 10.71
Current: 3.73
0.18
10.71
PFCF 27.51
CBM's PFCF is ranked higher than
67% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. CBM: 27.51 )
Ranked among companies with meaningful PFCF only.
CBM' s 10-Year PFCF Range
Min: 4.81  Med: 14.53 Max: 245.33
Current: 27.51
4.81
245.33
POCF 15.92
CBM's POCF is ranked higher than
76% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. CBM: 15.92 )
Ranked among companies with meaningful POCF only.
CBM' s 10-Year POCF Range
Min: 2.94  Med: 10.50 Max: 65
Current: 15.92
2.94
65
EV-to-EBIT 18.89
CBM's EV-to-EBIT is ranked higher than
65% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. CBM: 18.89 )
Ranked among companies with meaningful EV-to-EBIT only.
CBM' s 10-Year EV-to-EBIT Range
Min: -2271  Med: 11.20 Max: 388.4
Current: 18.89
-2271
388.4
PEG 2.15
CBM's PEG is ranked higher than
53% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. CBM: 2.15 )
Ranked among companies with meaningful PEG only.
CBM' s 10-Year PEG Range
Min: 0.52  Med: 1.28 Max: 42.7
Current: 2.15
0.52
42.7
Shiller P/E 42.96
CBM's Shiller P/E is ranked higher than
50% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 44.71 vs. CBM: 42.96 )
Ranked among companies with meaningful Shiller P/E only.
CBM' s 10-Year Shiller P/E Range
Min: 5.61  Med: 34.93 Max: 141.6
Current: 42.96
5.61
141.6
Current Ratio 2.33
CBM's Current Ratio is ranked lower than
70% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CBM: 2.33 )
Ranked among companies with meaningful Current Ratio only.
CBM' s 10-Year Current Ratio Range
Min: 0.9  Med: 2.53 Max: 5.19
Current: 2.33
0.9
5.19
Quick Ratio 1.16
CBM's Quick Ratio is ranked lower than
81% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CBM: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
CBM' s 10-Year Quick Ratio Range
Min: 0.5  Med: 1.42 Max: 4.55
Current: 1.16
0.5
4.55
Days Inventory 155.77
CBM's Days Inventory is ranked lower than
62% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. CBM: 155.77 )
Ranked among companies with meaningful Days Inventory only.
CBM' s 10-Year Days Inventory Range
Min: 107.67  Med: 132.76 Max: 228.78
Current: 155.77
107.67
228.78
Days Sales Outstanding 43.26
CBM's Days Sales Outstanding is ranked higher than
68% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CBM: 43.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBM' s 10-Year Days Sales Outstanding Range
Min: 49.84  Med: 58.63 Max: 112.79
Current: 43.26
49.84
112.79

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 112.10
CBM's Price/Net Current Asset Value is ranked lower than
97% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. CBM: 112.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CBM' s 10-Year Price/Net Current Asset Value Range
Min: 2.47  Med: 54.82 Max: 107.17
Current: 112.1
2.47
107.17
Price/Tangible Book 6.52
CBM's Price/Tangible Book is ranked lower than
59% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. CBM: 6.52 )
Ranked among companies with meaningful Price/Tangible Book only.
CBM' s 10-Year Price/Tangible Book Range
Min: 1.63  Med: 3.69 Max: 14.13
Current: 6.52
1.63
14.13
Price/Projected FCF 3.13
CBM's Price/Projected FCF is ranked higher than
58% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CBM: 3.13 )
Ranked among companies with meaningful Price/Projected FCF only.
CBM' s 10-Year Price/Projected FCF Range
Min: 0.83  Med: 2.18 Max: 12.66
Current: 3.13
0.83
12.66
Price/Median PS Value 2.97
CBM's Price/Median PS Value is ranked lower than
88% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. CBM: 2.97 )
Ranked among companies with meaningful Price/Median PS Value only.
CBM' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 1.15 Max: 7.37
Current: 2.97
0.21
7.37
Price/Peter Lynch Fair Value 1.51
CBM's Price/Peter Lynch Fair Value is ranked higher than
55% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. CBM: 1.51 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CBM' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56  Med: 1.29 Max: 8.25
Current: 1.51
0.56
8.25
Price/Graham Number 2.53
CBM's Price/Graham Number is ranked higher than
59% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. CBM: 2.53 )
Ranked among companies with meaningful Price/Graham Number only.
CBM' s 10-Year Price/Graham Number Range
Min: 0.43  Med: 1.62 Max: 4.96
Current: 2.53
0.43
4.96
Earnings Yield (Greenblatt) (%) 5.31
CBM's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CBM: 5.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CBM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 8.10 Max: 222.1
Current: 5.31
0.3
222.1
Forward Rate of Return (Yacktman) (%) 16.32
CBM's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 13.70 vs. CBM: 16.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CBM' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -42.4  Med: -7.80 Max: 21
Current: 16.32
-42.4
21

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 420 478
EPS($) 1.95 2.32
EPS without NRI($) 1.95 2.32

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XBX.Germany,
Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in a wide range of chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are supplied globally to innovator and generic drug companies. Products include APIs, pharmaceutical intermediates and, to a lesser extent, other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Cambrex to Present at the Wells Fargo Securities 2015 Healthcare Conference Sep 02 2015
Cambrex to Present at the Wells Fargo Securities 2015 Healthcare Conference Sep 02 2015
Cambrex Corp. Earnings Analysis: By the Numbers Q2, 2015 Aug 31 2015
CAMBREX CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 21 2015
Abiomed, Cambrex Show Why Bigger Isn't Always Better Aug 13 2015
CAMBREX CORP Financials Aug 06 2015
10-Q for Cambrex Corp. Aug 01 2015
Edited Transcript of CBM earnings conference call or presentation 30-Jul-15 12:00pm GMT Jul 31 2015
Cambrex Corp Earnings Call scheduled for 8:00 am ET today Jul 30 2015
Cambrex posts 2Q profit Jul 30 2015
Cambrex posts 2Q profit Jul 30 2015
CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 30 2015
Cambrex Reports Second Quarter 2015 Financial Results Jul 30 2015
Q2 2015 Cambrex Corp Earnings Release - Before Market Open Jul 30 2015
Cambrex Reports Second Quarter 2015 Financial Results Jul 30 2015
Cambrex to Announce Second Quarter 2015 Financial Results on July 30, 2015 Jul 28 2015
12 market-beating stocks from a 214-year-old strategy Jul 10 2015
Forget Biogen (BIIB), Buy These 3 Biotechnology Stocks Instead - Stocks in the News Jul 06 2015
The Zacks Analyst Blog Highlights: NeoPhotonics, Isle of Capri Casinos, Cambrex, Ambarella and... Jul 06 2015
7 Hot Growth Stocks that Have Outrun the Market in 1H15 - Analyst Blog Jul 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK